Literature DB >> 15666195

Prognostic factors affecting the natural history of node-negative breast cancer.

Maureen E Trudeau1, Kathleen I Pritchard, Judy-Anne W Chapman, Wedad M Hanna, Harriette J Kahn, David Murray, Carol A Sawka, Betty G Mobbs, Irene Andrulis, David R McCready, H Lavina Lickley.   

Abstract

PURPOSE: We undertook a natural history investigation of a broad selection of prognostic factors in a cohort of women with node-negative breast cancer. PATIENTS AND METHODS: The cohort consisted of 415 consecutive histologic node-negative (T1-3, M0) patients, operated on for primary breast cancer at Women's College Hospital, Toronto, Canada, between 1977 and 1986. Only 7% of these patients were given adjuvant systemic therapy; further, for the 48% of women who underwent lumpectomy, only 29% received adjuvant radiotherapy to the breast. Paraffin-embedded tumour tissue was available for the majority of patients. The following factors were examined for their univariate and multivariate effects on time to recurrence outside the breast (DFI) and survival from breast cancer (DSS): age, weight, tumour size, estrogen receptor, progesterone receptor, histologic type, tumour grade, nuclear grade, lymphovascular invasion, overexpression of neu oncoprotein, DNA ploidy, % cells in S-phase, and adjuvant therapy. Multivariate analyses utilized a Cox model with a step-wise factor selection for the 260 patients with complete information.
RESULTS: A worse prognosis was indicated when there was lymphovascular invasion (for DFI, p < 0.001; for DSS, p = 0.0046), high %S-phase (for DFI, p = 0.08; for DSS, p = 0.02), high tumour grade (for DFI, p = 0.02; for DSS, p = 0.03), and overexpression of neu oncoprotein (for DSS, p = 0.07).
CONCLUSIONS: In our natural history investigation, two factors, lymphovascular invasion and tumour grade, are of particular interest since they may be readily incorporated into clinical practice. Overexpression of neu oncoprotein may also play a role in determining prognosis for women administered adjuvant systemic therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15666195     DOI: 10.1007/s10549-004-1368-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.

Authors:  A Eisen; G G Fletcher; S Gandhi; M Mates; O C Freedman; S F Dent; M E Trudeau
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

2.  Correlation between minimum apparent diffusion coefficient values and the histological grade of breast invasive ductal carcinoma.

Authors:  Suhong Zhao; Weihua Guo; Ru Tan; Peipei Chen; Zhaohua Li; Fengguo Sun; Guangrui Shao
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

3.  Competing risks of death in younger and older postmenopausal breast cancer patients.

Authors:  Judy-Anne W Chapman; Kathleen I Pritchard; Paul E Goss; James N Ingle; Hyman B Muss; Susan F Dent; Ted A Vandenberg; Brian Findlay; Karen A Gelmon; Carolyn F Wilson; Lois E Shepherd; Michael N Pollak
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Genomic grade index is associated with response to chemotherapy in patients with breast cancer.

Authors:  Cornelia Liedtke; Christos Hatzis; William Fraser Symmans; Christine Desmedt; Benjamin Haibe-Kains; Vicente Valero; Henry Kuerer; Gabriel N Hortobagyi; Martine Piccart-Gebhart; Christos Sotiriou; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

5.  Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less.

Authors:  Ji Hyun Kwon; Yu Jung Kim; Keun-Wook Lee; Do-Youn Oh; So Yeon Park; Jee Hyun Kim; Eui Kyu Chie; Sung-Won Kim; Seock-Ah Im; In-Ah Kim; Tae-You Kim; In Ae Park; Dong-Young Noh; Yung-Jue Bang; Sung Whan Ha
Journal:  BMC Cancer       Date:  2010-10-15       Impact factor: 4.430

6.  Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.

Authors:  Sun Young Chae; Seol Hoon Park; Hyo Sang Lee; Jin-Hee Ahn; Sung-Bae Kim; Kyung Hae Jung; Jeong Eun Kim; Sei Hyun Ahn; Byung Ho Son; Jong Won Lee; Beom Seok Ko; Hee Jeong Kim; Gyungyub Gong; Jungsu S Oh; Seo Young Park; Dae Hyuk Moon
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

7.  Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development.

Authors:  Luay Aswad; Surya Pavan Yenamandra; Ghim Siong Ow; Oleg Grinchuk; Anna V Ivshina; Vladimir A Kuznetsov
Journal:  Oncotarget       Date:  2015-11-03

8.  Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.

Authors:  Ines Zemni; Montassar Ghalleb; Ichraf Jbir; Maher Slimane; Jamel Ben Hassouna; Tarek Ben Dhieb; Hatem Bouzaiene; Khaled Rahal
Journal:  World J Surg Oncol       Date:  2017-11-23       Impact factor: 2.754

9.  Prognostic validation and therapeutic decision-making of the AJCC eighth pathological prognostic staging for T3N0 breast cancer after mastectomy.

Authors:  San-Gang Wu; Jun Wang; Jian Lei; Chen-Lu Lian; Li Hua; Juan Zhou; Zhen-Yu He
Journal:  Clin Transl Med       Date:  2020-04-23

10.  Analysis of the potent prognostic factors in luminal-type breast cancer.

Authors:  Han-Sung Kim; Inseok Park; Hyun Jin Cho; Geumhee Gwak; Keunho Yang; Byung Noe Bae; Ki Whan Kim; Sehwan Han; Hong-Joo Kim; Young-Duck Kim
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.